Publications by authors named "K Laribi"

Claim this Profile
P
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Jennifer A Woyach, Lugui Qiu, Sebastian Grosicki, Tomasz Wrobel, Marcelo Capra, Kamel Laribi

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late toxicity and long-term efficacy of first-line bendamustine and rituximab combination in patients with Waldenström macroglobulinemia.
Véronique Leblond, Jean-Richard Eveillard, Driss Chaoui, Doriane Cavalieri, Caroline Dartigeas, Kamel Laribi

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.
David Vallois, Edoardo Missiaglia, Luis Veloza, Anja Fischer, Doriane Cavalieri, Kamel Laribi

Leukemia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, Vladimir Ivanov

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Waldenström's macroglobulinemia: The LYSA pragmatic guidelines.
Damien Roos-Weil, Cécile Tomowiak, Stéphanie Poulain, Florence Nguyen-Khac, Florian Bouclet, Kamel Laribi

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis